Loring Wolcott & Coolidge Fiduciary Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-59	Closed	-$6K	–	791
2021 Q3	$6K	Hold	59	–	–	﹤0.01%	651
2021 Q2	$6K	Buy	+59	New	+$5.43K	﹤0.01%	730

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's HZNP Position: Q4 2021 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2021, closing a stake of 59 shares — an estimated $6K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in HZNP in Q2 2021 and held it in 2 quarters. The position peaked at $6K in Q3 2021. 611 funds tracked by Wall St. Rank hold HZNP as of Q4 2021.

Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2021 after selling out during the quarter.
Loring Wolcott & Coolidge Fiduciary Advisors sold 59 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2021, an estimated $6K.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2021 and held it in 2 quarters.
Loring Wolcott & Coolidge Fiduciary Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $6K in Q3 2021.
611 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2021.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.